Articles from Baszucki Group

Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. The program, titled “LIVE IT~LAUNCH IT: Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health in Your Patients For Health Care Workers” is led by Deanna Kelly, PharmD, BCPP, the Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research and Director of the Maryland Psychiatric Research Center at the University of Maryland School of Medicine. This initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and research settings.

Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry.

The promise of ketogenic therapy for treating mental illness is accelerating with the newly published findings of a pilot study at The Ohio State University, which showed remarkable improvements in symptoms of depression in college students who maintained a ketogenic diet. This is the third recent study to show significant improvements in mental and physical health through ketogenic therapy.

Baszucki Group today announced the launch of two new initiatives across multiple sites exploring the effectiveness of ketogenic therapy for children and adolescents with bipolar disorder. The participating groups include a family resource center and four academic research institutions offering specialty programs devoted to treating serious mental illness in children and adolescents. Both programs are pioneering metabolic research with pediatric bipolar patients. These projects aim to develop ketogenic therapy programs and establish pilot data to fuel future randomized control trials and support programs in a youth population.

Baszucki Group announces a collaboration with Mayo Clinic to support a clinical trial investigating ketogenic therapy for bipolar disorder. This important study will further explore the intersection of metabolic and mental health along with cardio-metabolic implications, with the goal of informing the development of an interdisciplinary precision nutrition clinical service.

Baszucki Group today announced a new pilot study on a ketogenic diet in bipolar disorder. “For the first time in years, I felt like my brain was finally running on the right fuel,” said one of the study participants. Published today in BJPsych Open, the study is the first to use neuroimaging to demonstrate that a ketogenic diet may improve brain metabolism in individuals with a bipolar disorder diagnosis. With over 100 years of evidence of efficacy in epilepsy, a ketogenic diet is now being studied around the world for a variety of psychiatric and neurological conditions.